NovaBio: Net profit in the third quarter is expected to increase by 100.56% to 180.78% year-on-year.

Jinshi data news on October 7th, Notai Biology released performance forecast, it is expected that the net profit attributable to the owner of the parent company in the third quarter of 2024 will be 100 million to 140 million, an increase of 100.56% to 180.78% year-on-year. During the reporting period, the sales revenue of the company's polypeptide bulk drugs increased significantly compared to the same period last year.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)